Posted by Michael Wonder on 16 Mar 2017
Sunovion submits supplemental new drug application to FDA for use of Aptiom (eslicarbazepine acetate) for the treatment of partial-onset seizures in children 4 years of age and older
15 March 2017 - If approved, Aptiom would provide an important new monotherapy or adjunctive therapy treatment option for individuals as early as four years of age who experience partial-onset seizures.
Sunovion Pharmaceuticals today announced that it has submitted a supplemental new drug application (sNDA) to the U.S. FDA to expand the indication for its anti-epileptic drug Aptiom (eslicarbazepine acetate) to include use as monotherapy or adjunctive therapy for the treatment of partial-onset seizures in children four years of age and older.
